George M. Church is professor of genetics at Harvard Medical School, a founding member of the Wyss Institute, and director of PersonalGenomes.org, the world’s only open-access information on human genomic, environmental, and trait data. He is widely recognized for his innovative contributions to genomic science and his many pioneering contributions to chemistry and biomedicine. He developed the first methods for the first genome sequence and dramatic cost reductions since then (down from $3 billion to $600), contributing to nearly all “next generation sequencing” methods and companies. His honors include the Franklin Bower Laureate for Achievement in Science, the Time 100, and election to the National Academies of Sciences and Engineering. His many innovations have been the basis for 514 papers, 143 patent publications, and founder of 28 companies.
Gregory Verdine is Erving Professor of Chemistry in the Departments of Stem Cell and Regenerative Biology and Chemistry and Chemical Biology, a pioneer in the field of chemical biology, a serial biotech entrepreneur and a life science venture capitalist. He is a leading figure in the field of new therapeutic modalities, and has developed a new class of therapeutics termed stapled peptides, which are currently in clinical development and have received much attention for their ability to drug targets previously considered “undruggable.”
Dr. Verdine has made important contributions in the translation of bench science to the bedside. He has founded or co-founded a number of successful biotechnology companies, and has also worked in the venture capital industry as a Venture Partner with Apple Tree Partners, Third Rock Ventures, and WuXi Healthcare Ventures, and as a Special Advisor to Texas Pacific Group.
Dr. Verdine is Chairman of the Board of Directors of WaVe Life Sciences, and is a Director of Warp Drive Bio, for which he also Chairs the company’s Scientific Advisory Board. He is currently President and CEO of FogPharma, a biotechnology company focused on a transformative drug discovery platform based on Cell-Penetrating Miniproteins. Dr. Verdine serves on the Board of Scientific Consultants of the Memorial Sloan-Kettering Research Institute and on the Board of Scientific Advisors of the National Cancer Institute.